USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Neuroloop Gmbh

USPTO PatentsView assignee record - 22 granted patents across 11 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

The verdict

According to USPTO PatentsView, Neuroloop ranks #13,573 of 50,000 tracked US assignees by granted-patent volume, with 22 patents across 11 technology areas.

#13,573
of 50,000 US assignees by volume
Top 9%
by Innovation Score (53.6/100)
18.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R13573 · Foreign Corporation #13,573 · 22 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-SMALL 22 grants
  • MID-PACK #13,573/50,000
  • PHOTO-FINISH Motiv Power Systems
  • CPC-FOCUS A61N · 11 areas
  • INNOV-PAR 53.6/100
  • CLAIMS-RICH 18.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Motiv Power Systems, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Neuroloop

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Neuroloop Gmbh stamps GRANTS-SMALL, MID-PACK, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-RICH, TYPE-FRNCORP, SPAN-YRS, BOOK-RICH. Volume places it #13,573 of 50,000; Innovation Score 53.6/100 sits in the top 9% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Motiv Power Systems, Inc. (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

Neuroloop Gmbh has been granted 22 US utility patents between 2020 and 2025, placing Neuroloop Gmbh at #13,573 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.4 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Neuroloop Gmbh is one of the more focused assignees in the PatentsView dataset. By volume, Neuroloop sits between Motiv Power Systems, Inc. (22 patents, rank #13,563) and NIO Co., Ltd. (22 patents, rank #13,571) - the closest US assignees by grant volume. The composite Innovation Score of 53.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2020 through 2025, with 22 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Neuroloop Gmbh's 18.4 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 11 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Neuroloop's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Neuroloop holds 22 patents at rank #13,567, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Neuroloop

By rank, the assignees closest to #13,567 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Neuroloop's primary technology class.

Neuroloop's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 9% higher than 91% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0246810 202020212022202320242025 5
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Neuroloop Gmbh patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 3 13.6%
2021 1 4.5%
2022 4 18.2%
2023 8 36.4%
2024 1 4.5%
2025partial year 5 22.7%

Where it ranks

Overall rank by patents

#13,573

of 50,000 tracked assignees

Innovation Score

53.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.